Outpatient Prospective Payment System & Ambulatory Surgical Center (OPPS/ASC)

Analysis updated November 9, 2026

Strategic questions for your team

Given that OPPS pays under Medicare Part B as a hybrid of prospective APC rates and fee-schedule payments — with packaged services receiving no separate payment (status indicator 'N') while pass-through drugs (status indicator 'G') and non-pass-through separately payable drugs (status indicator 'K') are reimbursed on top of APC rates — have we mapped every high-volume service line to its specific APC payment rate and status indicator to identify where our true cost-to-reimbursement gaps exist, particularly for high-cost new technology APCs ranging from Level 3 ($101–$200) through Level 43 ($40,001–$50,000)?
Effective September 1, 2025, short-stay inpatient admission medical reviews and patient status reviews transferred from BFCC-QIOs to Medicare Administrative Contractors (MACs) operating under the Targeted Probe and Educate (TPE) program — do we have the physician documentation protocols, case management workflows, and compliance infrastructure in place to withstand MAC scrutiny of admissions that do not meet the Two-Midnight benchmark, particularly for stays expected to last less than two midnights that we are admitting under the case-by-case physician judgment exception?
The CY 2026 OPPS/ASC final rule (90 FR 53448, published November 25, 2025) resumed phased elimination of the Inpatient-Only (IPO) list, and the CY 2027 OPPS/ASC final rule (CMS-1850-F, effective January 1, 2027) continues this trajectory with expanded surgical options — have we identified which specific procedures in our surgical mix are candidates for IPO removal, modeled the reimbursement differential between IPPS and OPPS/ASC rates for those procedures, and assessed whether our outpatient infrastructure can safely perform them at volume, taking into account expert criticism that IPO list elimination conflates site-neutral payment policy with patient safety considerations?
For all separately payable single-dose container drugs billed under OPPS (status indicators 'G' or 'K') and ASC (payment indicator 'K2'), are we fully compliant with the JW/JZ modifier requirements — specifically, are we reporting the JW modifier for all discarded amounts, the JZ modifier (mandatory no later than July 1, 2023, with unprocessable claim risk from October 1, 2023) for zero-discard claims, documenting discarded amounts in the medical record, and have we quantified our exposure to claim returns and manufacturer refund calculations driven by JW modifier data under the Infrastructure Investment and Jobs Act (Pub. L. 117-9)?
With telehealth flexibilities under the Full-Year Continuing Appropriations and Extensions Act, 2025 — including home-based originating sites, expanded practitioner eligibility (PTs, OTs, SLPs, audiologists), audio-only capability, and suspension of frequency limits on subsequent inpatient and nursing facility visits — currently authorized only through September 30, 2025, have we modeled the revenue and operational impact of a cliff-edge expiration, identified which OPPS-billed remote therapy, DSMT, and MNT services would lose hospital billing eligibility, and developed contingency plans if Congress does not extend these provisions?
For off-campus provider-based departments (PBDs) billing under OPPS, have we confirmed that each department either qualifies as 'excepted' under Section 603 of the Bipartisan Budget Act of 2015 (i.e., was billing prior to November 2, 2015, is a dedicated ED, is within 250 yards of the main campus, or qualifies under the 21st Century Cures Act Sections 16001/16002), and if any department has relocated or is considering relocation due to extraordinary circumstances, have we submitted or prepared a timely relocation exception request to our CMS Regional Office — given that non-excepted services are paid under the Medicare Physician Fee Schedule rather than the higher OPPS rates, and given that the CY 2027 final rule expands site-neutral payment policies that may further compress non-excepted PBD rates?
For cataract surgery programs billing premium intraocular lenses, have we verified that every PC IOL, AC IOL, or PC/AC IOL we implant appears on the current CMS Recognized IOL list (last updated March 2026) under CMS Rulings 05-01 and 1536-R, and do we have a patient cost-sharing disclosure and billing workflow that correctly separates the Medicare-covered monofocal IOL equivalent payment from the patient-pay differential for premium lens upgrades to avoid compliance exposure?
For high-cost new technology APCs where observed geometric mean costs in the CY 2025 claims data (January–September 2025, analyzed February 19, 2026) are significantly below the APC payment band — for example, APC 1580O (Level 43, $40,001–$50,000 range) showing procedures like cranial nerve implants at $46,339 geometric mean cost and phrenic nerve stimulation at $48,869 — have we performed service-line contribution margin analysis accounting for device costs, implant acquisition, OR time, and ancillary packaging to determine whether performing these procedures in the hospital outpatient versus inpatient setting is financially viable at current OPPS rates?
Given that OPPS drug payment rates based on Average Sales Price (ASP) methodology are subject to quarterly retroactive correction — with restated payment rates published via the OPPS quarterly update change request beginning January 2015 — do we have a revenue cycle process to monitor CMS's 'Restated Drug and Biological Payment Rates' page each quarter, identify retroactive rate changes affecting previously submitted claims, and execute timely claim adjustments to capture owed payments or repay overpayments before MAC audit exposure accrues?
CMS has added 10 new procedure codes to the ASC-covered procedures list — have we assessed each newly eligible code against our current ASC service mix, modeled the ASC payment rate versus HOPD rate differential for those procedures, evaluated whether our ASC physical plant and staffing can support safe performance at volume, and updated our chargemaster and billing workflows to activate the new codes before the applicable effective date?
The CY 2027 OPPS/ASC final rule (CMS-1850-F, effective January 1, 2027) finalizes a 2.3% payment rate increase and expands site-neutral payment policies — have we modeled the net financial impact of the 2.3% update against our specific service mix, assessed how expanded site-neutral provisions will affect payment rates for non-excepted off-campus PBDs and other affected settings, and updated our strategic planning assumptions to reflect the new payment environment beginning January 1, 2027?
The CY 2027 OPPS/ASC final rule reduces 340B drug reimbursement rates and lowers patient out-of-pocket costs for 340B drugs — have we quantified the financial impact of the 340B rate reduction on our hospital outpatient drug revenue, assessed the downstream effect on our 340B program's contribution margin, and evaluated whether continued participation in 340B-eligible drug purchasing remains strategically optimal given the revised reimbursement structure?
The October 2026 OPPS quarterly update (Transmittal R13978CP, CR 14589, implementation date October 5, 2026) may have introduced APC rate revisions, status indicator changes, or packaging edits affecting our current service lines — have we reviewed the transmittal in detail, updated our chargemaster and claims editing system accordingly, and assessed whether any changes materially alter the contribution margin of high-volume or high-cost procedure lines?
New cost report requirements mandate reporting of Medicare Advantage negotiated rates — have we established a data collection and reconciliation process to accurately report MA negotiated rates on the cost report, assessed the downstream implications for wage index calculations, DSH determinations, and outlier payment thresholds, and evaluated whether disclosure of MA rates creates strategic or competitive exposure?
CMS has introduced a new Emergency Care Access and Treatment (ECAT) quality measure under OPPS — have we assessed the operational and documentation requirements of the ECAT measure, modeled the financial risk of non-compliance or low performance on OPPS payment updates, and determined whether our emergency department workflows and data infrastructure can meet the reporting standards required?

Traps and concerns

Two-Midnight MAC Review Migration Risk
Effective September 1, 2025, short-stay inpatient hospital medical reviews and patient status reviews transferred from BFCC-QIOs to Medicare Administrative Contractors (MACs) operating under the Targeted Probe and Educate (TPE) program. MACs now review samples of Medicare Part A claims per Medicare Program Integrity Manual (PIM) 100-8 Chapter 6 and Exhibit 48. Hospitals that calibrated their utilization review workflows to BFCC-QIO audit patterns, appeal procedures, and documentation expectations must now re-engineer those processes for MAC-specific TPE protocols, which operate iteratively and can escalate to prepayment review if probe rounds reveal sustained error rates. Failure to adapt documentation standards—particularly physician attestation of medical necessity for stays under two midnights—risks claim denials and potential extrapolated overpayment demands across sampled claim cohorts.
JW/JZ Modifier Compliance Audit Exposure
Since October 1, 2023, claims for separately payable single-dose container drugs billed under OPPS status indicators 'G' or 'K' (and ASC payment indicator 'K2') that omit the JW modifier (discarded drug) or JZ modifier (zero waste attestation) are returned as unprocessable. In the OPPS setting, only separately payable drugs require these modifiers—packaged drugs under status indicator 'N' are explicitly excluded. However, billing staff frequently misclassify packaged vs. separately payable drugs, creating dual exposure: (1) unprocessed claims generating immediate cash flow gaps, and (2) retrospective audits for dates of service back to January 1, 2017 for JW non-compliance. Non-BLA skin substitutes reclassified as incident-to supplies effective January 1, 2026 are now explicitly prohibited from JW billing for discarded amounts, creating a new category of overpayment risk for facilities that have not updated charge capture rules. The Infrastructure Investment and Jobs Act (P.L. 117-9) mandates manufacturer refunds calculated from JW modifier data, meaning CMS has strong programmatic incentive to enforce these audits rigorously.
ASP Quarterly Retroactive Drug Rate Corrections
OPPS drug and biological payment rates based on Average Sales Price (ASP) methodology are subject to retroactive quarterly correction, a process formalized beginning with the January 2015 quarterly update. Facilities that book revenue at initial payment rates for high-volume separately payable drugs face material reconciliation risk when corrected rates are published. The CY 2027 preliminary ratesetting data (using CY 2025 claims through September, published February 19, 2026) shows pemivibart infusion (M0224) with a geometric mean cost of $1,120.63 across 339 claims in APC 1506, and esketamine visits (G2083) generating 4,015 claims at $1,643.98 average in APC 1518. Even modest ASP corrections on high-frequency codes at these payment levels generate six- to seven-figure reconciliation variances at volume hospitals. Finance teams without automated quarterly rate-monitoring systems will systematically mis-state net revenue and may face clawback demands from MACs on reopened claims.
Section 603 Off-Campus PBD Excepted Status Forfeiture
Under Section 603 of the Bipartisan Budget Act of 2015, off-campus provider-based departments (PBDs) not billing for covered OPD services prior to November 2, 2015 are non-excepted and paid under the Medicare Physician Fee Schedule rather than OPPS rates—a differential that can represent 30-50% lower reimbursement per service line. Excepted PBDs that relocate without obtaining a CMS Regional Office extraordinary circumstance exception lose excepted status permanently; that determination is final and not subject to appeal under Section 1833(t)(21)(E)(ii). Hospitals undergoing facility consolidations, seismic retrofits, or disaster relocations must file exception requests no later than 30 days after the triggering event for post-January 1, 2017 relocations. Health systems that acquire previously non-excepted off-campus departments and attempt to re-bill under OPPS rates face False Claims Act exposure in addition to recoupment of OPPS overpayments retroactive to the acquisition date. The CY 2027 OPPS final rule (CMS-1850-F) finalizes expanded site-neutral payment policies that increase the financial gap between excepted and non-excepted PBD status, raising the stakes of any excepted status forfeiture.
Inpatient-Only List Phased Elimination IPO Transition Risk
The CY 2026 OPPS/ASC final rule (90 FR 53448) re-initiated phased elimination of the Inpatient-Only (IPO) list, reversing the CY 2022 decision to halt elimination. Procedures removed from the IPO list beginning January 1, 2021 retain an indefinite medical review exemption—confirmed in CY 2026 rulemaking—until the Secretary determines the procedure is more commonly performed in the outpatient setting for the Medicare population. As additional high-acuity procedures migrate off the IPO list in subsequent years, hospitals face three simultaneous pressures: (1) surgical scheduling and pre-authorization workflows must be rebuilt to accommodate outpatient designation for previously inpatient-only cases; (2) ASC operators must evaluate capital and staffing adequacy for newly eligible complex procedures; and (3) beneficiaries converted from Part A inpatient to Part B outpatient status lose SNF benefit eligibility (the three-day qualifying stay requirement), creating patient financial counseling obligations and potential liability for inadequate advance notice under the MOON (Medicare Outpatient Observation Notice) requirements. Expert commentary from former MedPAC staff published in September 2026 argues that site-neutral payment objectives do not require IPO list elimination and that CMS may be conflating distinct policy goals—signaling a potential avenue for industry challenge in future rulemaking that hospitals should monitor. The CY 2027 OPPS final rule (CMS-1850-F) continues this trajectory by expanding surgical options in ASC settings, reinforcing the operational urgency for facilities to continuously update procedure eligibility frameworks.
CY 2027 Site-Neutral Payment Expansion Reimbursement Risk
The CY 2027 OPPS final rule (CMS-1850-F, effective January 1, 2027) finalizes expanded site-neutral payment policies that reduce reimbursement for services furnished at off-campus, non-excepted provider-based departments. The AHA has formally objected to these changes, characterizing the finalized policies as financially harmful to hospitals and inconsistent with Congressional intent. Health systems with significant revenue exposure through non-excepted PBDs face compounding risk: (1) the site-neutral differential effectively shrinks the OPPS rate premium that historically justified the provider-based department model; (2) facilities that have not modeled the revenue impact of expanded site-neutral application to their specific service mix may face budget variances beginning January 1, 2027; and (3) the AHA's public opposition signals active litigation or legislative challenge risk, meaning facilities should not plan capital expenditures around current non-excepted PBD revenue assumptions that could shift further in subsequent rulemaking. The 2.3% aggregate payment update does not offset site-neutral losses for facilities heavily weighted toward non-excepted outpatient departments.
New Technology APC Geometric Mean Misalignment
CMS assigns new technology APCs based on geometric mean cost ranges derived from claims data, but the CY 2027 preliminary ratesetting file (CY 2025 claims, January–September, published February 19, 2026) reveals systemic volume sparsity that undermines rate accuracy. APC 1580O (New Technology Level 43, $40,001–$50,000, marked OFFLINE) shows a geometric mean of $44,490.53 across only 404 claims for codes including 0266T (carotid sinus stimulator implant, $42,767.66, 223 claims) and 64568 (cranial nerve electrode implant, $46,339.31, 151 claims). APC 1579 (Level 42, $30,001–$40,000) shows 0686T (hepatic histotripsy, $14,670.03 geometric mean) with 126 claims against a labeled APC range of $30,001–$40,000—a clear rate-to-cost misalignment. Hospitals that adopt high-cost new technology procedures based on current APC assignments face revenue shortfalls when low claims volumes cause CMS to recalibrate or reclassify APCs in subsequent rulemaking cycles, with no prospective notice period between proposed and final rule implementation.
ASC Approved Procedure List Expansion Operational Risk
CMS added 10 procedure codes to the ASC covered procedures list effective with the October 2026 OPPS update (CMS Transmittal R13978CP, CR 14589, implementation date October 5, 2026), and the CY 2027 OPPS final rule (CMS-1850-F) further expands surgical options available in ASC settings effective January 1, 2027. ASC operators that have not updated their internal procedure eligibility databases, credentialing matrices, and payer contract fee schedules to reflect these additions risk two compounding harms: (1) failure to bill newly eligible procedures under ASC payment rates, leaving facility fee revenue uncaptured; and (2) inadvertent performance of a newly listed procedure without confirming adequate staffing, equipment, and post-operative monitoring capabilities, creating patient safety and accreditation exposure. CMS continues to expand the ASC-covered list in both the annual OPPS/ASC final rule cycle and mid-year transmittals; facilities should treat mid-year additions as a distinct compliance track requiring quarterly charge description master (CDM) reconciliation separate from the January 1 annual update process.
340B Drug Payment Rate Reduction in CY 2027
The CY 2027 OPPS final rule (CMS-1850-F) finalizes changes to 340B drug payment rates, reducing reimbursement for 340B-acquired drugs furnished in the hospital outpatient setting. CMS's stated rationale is lowering out-of-pocket costs for beneficiaries, but the operational impact for 340B-covered entities is a narrowing of the spread between acquisition cost and Medicare reimbursement that has historically cross-subsidized safety-net services. Hospitals relying on 340B savings to fund uncompensated care, charity care programs, or low-margin service lines must model the net revenue impact of reduced OPPS 340B rates on their CY 2027 budgets. The AHA has objected to the finalized 340B changes, signaling ongoing litigation risk—but facilities should not defer compliance planning pending legal outcomes, as prior 340B litigation cycles have shown multi-year resolution timelines during which reduced rates remain operative.
MA Negotiated Rate Cost Report Disclosure Risk
CMS has introduced a new cost report requirement mandating that hospitals report Medicare Advantage (MA) negotiated rates. Facilities that have not established internal data pipelines to extract, validate, and report MA contract rates by payer and service line face cost report preparation failures and potential desk review scrutiny. Because MA negotiated rates often differ materially from Medicare fee-for-service rates—and may reflect volume discounts, risk arrangements, or bundled payment structures—inaccurate or incomplete reporting could distort cost-to-charge ratios used in OPPS and ASC rate-setting, triggering downstream ratesetting errors that affect all providers. Additionally, the disclosure of MA rates in cost reports creates a new transparency vector: once reported to CMS, these rates may inform future site-neutral or OPPS policy proposals, making accurate and strategically reviewed submission essential.